Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Status:
Withdrawn
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purposed of this research is to study the safety and clinical activity of the combination
of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins